Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change?

被引：0

作者：

Liu, Jinan

Thaker, Premal H.

Sah, Janvi

Maiese, Eric M.

Bee, Oscar

Hurteau, Jean

Chan, John

机构：

[1] GlaxoSmithKline, Navy Yard, PA USA

[2] Washington Univ, Sch Med, Dept Gynecol Oncol, St Louis, MO 63110 USA

[3] STATinMED Res, Ann Arbor, MI USA

[4] GlaxoSmithKline, Waltham, MA USA

[5] Palo Alto Med Fdn, Calif Pacific, Sutter Hlth, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 28期

关键词：

D O I：

10.1200/JCO.2020.39.28_suppl.294

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

294

引用

页数：4

共 50 条

[21] Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
Goh, Jeffrey C. H.
Gourley, Charlie
Tan, David S. P.
Nogueira-Rodrigues, Angelica
Elghazaly, Hesham
Pierre, Marc Edy
Giornelli, Gonzalo
Kim, Byoung-Gie
Morales-Vasquez, Flavia
Tyulyandina, Alexandra
GYNECOLOGIC ONCOLOGY REPORTS, 2022, 42
[22] Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A singlecenter retrospective study
Wenxin, L.
Wang, K.
Zhang, L.
Ma, Y.
Wu, H.
Chen, Y.
Bao, L.
Fu, X.
ANNALS OF ONCOLOGY, 2023, 34 : S1594 - S1594
[23] Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients
Sun, Gordon H.
Neary, Maureen P.
Chang, Eunice
Broder, Michael S.
PANCREAS, 2015, 44 (02) : 359 - 360
[24] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
Minmin Zhao
Shanhu Qiu
Xin Wu
Pengcheng Miao
Zhi Jiang
Tao Zhu
Xizhong Xu
Yanling Zhu
Bei Zhang
Donglan Yuan
Yang Zhang
Wei Sun
Aiqin He
Min Zhao
Wenjie Hou
Yingli Zhang
Zhuyan Shao
Meiqun Jia
Mei Li
Jun Chen
Jingcheng Xu
Bingwei Chen
Ying Zhou
Yang Shen
Targeted Oncology, 2023, 18 : 869 - 883
[25] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
Zhao, Minmin
Qiu, Shanhu
Wu, Xin
Miao, Pengcheng
Jiang, Zhi
Zhu, Tao
Xu, Xizhong
Zhu, Yanling
Zhang, Bei
Yuan, Donglan
Zhang, Yang
Sun, Wei
He, Aiqin
Zhao, Min
Hou, Wenjie
Zhang, Yingli
Shao, Zhuyan
Jia, Meiqun
Li, Mei
Chen, Jun
Xu, Jingcheng
Chen, Bingwei
Zhou, Ying
Shen, Yang
TARGETED ONCOLOGY, 2023, 18 (06) : 869 - 883
[26] Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: Real-world data from a multicenter study in China
Shen, Yang
GYNECOLOGIC ONCOLOGY, 2024, 190 : S317 - S317
[27] Newly diagnosed ovarian cancer: Which first-line treatment?
Lorusso, Domenica
Ceni, Valentina
Daniele, Gennaro
Salutari, Vanda
Pietragalla, Antonella
Muratore, Margherita
Nero, Camilla
Ciccarone, Francesca
Scambia, Giovanni
CANCER TREATMENT REVIEWS, 2020, 91
[28] Real-world treatment patterns among newly diagnosed myelofibrosis patients.
Yang, Yoojung
Lu, Mei
Hooper, Ellen
Feliciano, Joseph
Aly, Abdalla
Mesa, Ruben A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] REAL-WORLD TREATMENT PATTERNS AND OUTCOMES WITH FIRST-LINE MAINTENANCE OLAPARIB FOR BRCAM ADVANCED OVARIAN CANCER: A PAN-EUROPEAN STUDY (OVAL-1)
Gourley, C.
Asselain, B.
Garbay, D.
Lorusso, D.
Miller, R.
Condon, O.
Kertous, M.
Padrone, C.
Rigney, U.
Dube, S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A204 - A205
[30] PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China
Chen, Jinghong
Zhang, Mengpei
Li, Kemin
Duan, Yuanqiong
Zeng, Jing
Li, Qingli
Wang, Danqing
Song, Liang
Li, Qintong
Yin, Rutie
FRONTIERS IN ONCOLOGY, 2024, 14

← 1 2 3 4 5 →